(Q36814486)

16 August 2017

1 reference

title

Aromatase inhibitors for breast cancer (English)

1 reference

16 August 2017

Susanne Briest

1

1 reference

16 August 2017

Nancy E Davidson

series ordinal

2

1 reference

16 August 2017

publication date

1 September 2007

1 reference

Reviews in Endocrine and Metabolic Disorders

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

215-228

1 reference

https://scigraph.springernature.com/pub.10.1007/s11154-007-9039-z

16 August 2017

exact match

0 references

cites work

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11154-007-9039-Z

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

21 January 2018

1 reference

12 December 2020

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

12 December 2020

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines

1 reference

12 December 2020

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

12 December 2020

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

12 December 2020

Mammographic breast density as an intermediate phenotype for breast cancer

1 reference

12 December 2020

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

A phase I trial of CGS 16949A. A new aromatase inhibitor

1 reference

12 December 2020

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

1 reference

12 December 2020

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

12 December 2020

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

1 reference

12 December 2020

Aromatase inhibitor development and hormone therapy: a perspective

1 reference

12 December 2020

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

12 December 2020

Aromatase inhibitors for therapy of advanced breast cancer

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Novel concepts for the chemoprevention of breast cancer through aromatase inhibition

1 reference

12 December 2020

Estrogen receptors and breast cancer response to adrenalectomy

1 reference

12 December 2020

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

1 reference

12 December 2020

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

12 December 2020

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

1 reference

12 December 2020

Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.

1 reference

12 December 2020

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

1 reference

12 December 2020

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

12 December 2020

The pharmacology of letrozole

1 reference

12 December 2020

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

12 December 2020

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

1 reference

12 December 2020

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial

1 reference

12 December 2020

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

12 December 2020

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer

1 reference

12 December 2020

Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?

1 reference

12 December 2020

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

1 reference

12 December 2020

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

1 reference

12 December 2020

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial

1 reference

12 December 2020

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer

1 reference

12 December 2020

Breast cancer management: quality-of-life and cost considerations

1 reference

12 December 2020

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

12 December 2020

A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer

1 reference

12 December 2020

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o

1 reference

12 December 2020

Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

1 reference

12 December 2020

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

1 reference

12 December 2020

Endocrine-responsive breast cancer and strategies for combating resistance

1 reference

12 December 2020

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

1 reference

12 December 2020

Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient

1 reference

12 December 2020

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

12 December 2020

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

12 December 2020

10.1007/S11154-007-9039-Z

Identifiers

DOI

1 reference

16 August 2017

1 reference